## Aster DM Healthcare Limited (ASTERDM) Stock Analysis

This report analyzes the provided data for Aster DM Healthcare Limited (ASTERDM) to determine whether it is a buy, sell, or hold.  The analysis is based solely on the provided data and does not consider external market factors or sentiment.

**1. Data Preprocessing:**

The provided data has been parsed and organized into the following sections:

**1.1 Company Profile:**

| Field             | Value                               |
|----------------------|---------------------------------------|
| Symbol             | ASTERDM                             |
| Company Name       | Aster DM Healthcare Limited           |
| Industry           | Hospital                             |
| Listing Date       | 2018-02-26                           |
| ISIN               | INE914M01019                         |


**1.2 Market Data (as of 20-Dec-2024):**

| Metric                | Value     |
|------------------------|------------|
| Last Price             | 485.60     |
| Change                 | -6.25      |
| Percentage Change (%)  | -1.27%     |
| Previous Close         | 491.85     |
| Open                   | 494.45     |
| Close                  | 486.35     |
| VWAP                   | 498.22     |
| Week High              | 558       |
| Week Low               | 311.1      |
| Sector PE              | 54.07      |
| Symbol PE              | 54.07      |
| Intraday High          | 507.5      |
| Intraday Low           | 482.4      |
| Delivery to Traded (%) | 35.26%     |


**1.3 Pre-Open Market Data (20-Dec-2024):**

The pre-open market showed a final price of 494.45, a change of +2.60 and a percentage change of +0.53% compared to the previous close.  However, the actual opening price was slightly lower at 494.45.  This suggests some selling pressure at the open.

**1.4 Corporate Actions:**

| Ex-Date      | Purpose                               | Amount (Rs) |
|--------------|----------------------------------------|-------------|
| 22-Aug-2024  | Annual General Meeting/Dividend        | 2           |
| 23-Apr-2024  | Special Dividend                       | 118         |
| 23-Jan-2020  | Buy Back                               |  N/A        |


**1.5 Recent Announcements (Selection):**

* 12-Dec-2024: Acquisition-XBRL
* 12-Dec-2024: General Updates
* 12-Dec-2024: Acquisition
* 11-Dec-2024: Analysts/Institutional Investor Meet/Con. Call Updates


**1.6 Financial Results (Last Five Quarters):**

| Quarter End      | Income      | Expenditure | Profit After Tax | EPS      |
|-----------------|-------------|--------------|-------------------|----------|
| 30-Sep-2024     | 65,142      | 53,159       | 8,984            | 1.8      |
| 30-Jun-2024     | 618,513     | 52,034       | 600,824          | 120.67   |
| 31-Mar-2024     | 54,928      | 50,263       | -811             | -0.16    |
| 31-Dec-2023     | 53,783      | 48,464       | 5,319            | 1.07     |
| 30-Sep-2023     | 52,969      | 47,300       | 5,906            | 1.19     |

**Note:**  There's a significant discrepancy in income between Q2 2024 and other quarters. This needs further investigation to understand the reason for this outlier.


**1.7 Shareholding Patterns:**

Promoter holding has remained consistently at 41.88% over the last five quarters. Public shareholding has slightly increased.


**1.8 Key Directors and Contact Information:**

(See Appendix for detailed list of directors and contact information)


**2. Key Indicators:**

**2.1 Current Price Analysis:**

The current price (485.60) is below the previous close (491.85), indicating a downward trend. It's also significantly below the week high (558) and above the week low (311.1). The pre-open activity suggested a potential upward movement, but this was not sustained during the regular trading session.

**2.2 Financial Performance:**

Revenue shows significant volatility, with Q2 2024 being an extreme outlier. Profitability is also inconsistent, with a significant loss in Q1 2024. EPS follows a similar pattern.  The large difference in Q2 2024 income requires further investigation before drawing conclusions.

**2.3 Shareholding Analysis:**

Promoter holding remains stable, suggesting confidence in the company's future.  The slight increase in public holding might indicate increased investor interest, but more data is needed to confirm this.

**2.4 Corporate Action Summary:**

The company has declared significant dividends in the last year, which is positive for investors.

**2.5 Volatility and Risk:**

The CM Daily Volatility (2.28) and CM Annual Volatility (43.56) indicate moderate to high volatility, suggesting higher risk.

**3. Final Verdict:**

**Don't Buy.**

**Reasoning:**

While the company has declared substantial dividends and maintains stable promoter holdings, the significant inconsistencies in financial performance, particularly the outlier in Q2 2024 income, raise serious concerns.  The high volatility adds to the risk.  Until the reasons for the Q2 2024 financial results are clarified and a more consistent financial trend is established, investing in ASTERDM carries considerable risk.  Further investigation into the Q2 2024 figures is crucial before considering any investment.

**Conclusion:**

Based on the available data, ASTERDM presents a high-risk investment due to inconsistent financial performance and high volatility.  The significant discrepancy in Q2 2024's financial results requires further investigation before a different recommendation can be made.


**Appendix:**

**Key Management Personnel (as of 30-Sep-2024):**

(List of directors and their designations from the provided data)

**Contact Information:**

* **Registrar:** Link Intime India Private Limited (Contact details provided in the data)
* **Company Contact:** Aster DM Healthcare Limited (Contact details provided in the data)


**Note:** This analysis is based solely on the limited data provided.  A comprehensive investment decision should involve a much broader analysis, including external market factors, industry trends, and a deeper dive into the company's financials.
